CN1045294C - 吲哚衍生物的制备方法 - Google Patents

吲哚衍生物的制备方法 Download PDF

Info

Publication number
CN1045294C
CN1045294C CN92113491A CN92113491A CN1045294C CN 1045294 C CN1045294 C CN 1045294C CN 92113491 A CN92113491 A CN 92113491A CN 92113491 A CN92113491 A CN 92113491A CN 1045294 C CN1045294 C CN 1045294C
Authority
CN
China
Prior art keywords
indole
formula
ylamino
ylmethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92113491A
Other languages
English (en)
Chinese (zh)
Other versions
CN1072679A (zh
Inventor
J·E·梅卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1072679A publication Critical patent/CN1072679A/zh
Application granted granted Critical
Publication of CN1045294C publication Critical patent/CN1045294C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN92113491A 1991-11-25 1992-11-24 吲哚衍生物的制备方法 Expired - Fee Related CN1045294C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79674491A 1991-11-25 1991-11-25
US796,744 1991-11-25

Publications (2)

Publication Number Publication Date
CN1072679A CN1072679A (zh) 1993-06-02
CN1045294C true CN1045294C (zh) 1999-09-29

Family

ID=25168947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92113491A Expired - Fee Related CN1045294C (zh) 1991-11-25 1992-11-24 吲哚衍生物的制备方法

Country Status (30)

Country Link
US (1) US5639752A (cg-RX-API-DMAC7.html)
EP (1) EP0619805B1 (cg-RX-API-DMAC7.html)
JP (2) JP2840448B2 (cg-RX-API-DMAC7.html)
KR (1) KR0184911B1 (cg-RX-API-DMAC7.html)
CN (1) CN1045294C (cg-RX-API-DMAC7.html)
AT (1) ATE190608T1 (cg-RX-API-DMAC7.html)
AU (1) AU671959B2 (cg-RX-API-DMAC7.html)
BR (1) BR9206810A (cg-RX-API-DMAC7.html)
CA (1) CA2124206C (cg-RX-API-DMAC7.html)
CZ (1) CZ281874B6 (cg-RX-API-DMAC7.html)
DE (1) DE69230803T2 (cg-RX-API-DMAC7.html)
DK (1) DK0619805T3 (cg-RX-API-DMAC7.html)
EG (1) EG21209A (cg-RX-API-DMAC7.html)
ES (1) ES2143992T3 (cg-RX-API-DMAC7.html)
FI (1) FI942395A0 (cg-RX-API-DMAC7.html)
GR (1) GR3033370T3 (cg-RX-API-DMAC7.html)
HU (1) HUT69705A (cg-RX-API-DMAC7.html)
IL (1) IL103798A (cg-RX-API-DMAC7.html)
MX (1) MX9206762A (cg-RX-API-DMAC7.html)
MY (1) MY109954A (cg-RX-API-DMAC7.html)
NO (1) NO301225B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ245243A (cg-RX-API-DMAC7.html)
PL (1) PL173875B1 (cg-RX-API-DMAC7.html)
PT (1) PT101087B (cg-RX-API-DMAC7.html)
RU (1) RU2126399C1 (cg-RX-API-DMAC7.html)
TW (1) TW229205B (cg-RX-API-DMAC7.html)
UA (1) UA41297C2 (cg-RX-API-DMAC7.html)
WO (1) WO1993011106A1 (cg-RX-API-DMAC7.html)
YU (1) YU48456B (cg-RX-API-DMAC7.html)
ZA (1) ZA929082B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123955B (zh) * 2004-12-23 2012-05-30 艾尼纳制药公司 5HT2c受体调节剂组合物及其制药用途

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
CA2124206C (en) * 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
WO1993020073A1 (en) 1992-04-07 1993-10-14 Pfizer Inc. Indole derivatives as 5-ht1 agonists
JP2544704B2 (ja) * 1992-04-10 1996-10-16 フアイザー・インコーポレイテツド ５−ｈｔ▲下１▼アゴニストとしてのアシルアミノインド―ル誘導体
EP0651749A1 (en) * 1992-07-24 1995-05-10 MERCK SHARP & DOHME LTD. Imidazole, triazole and tetrazole derivatives
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
WO1995006636A1 (en) * 1993-08-31 1995-03-09 Pfizer Inc. 5-arylindole derivatives
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
EP0775131A2 (de) * 1994-08-03 1997-05-28 ASTA Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
FR2724933A1 (fr) * 1994-09-22 1996-03-29 Pf Medicament Nouveaux ethers aromatiques derives d'indoles utiles comme medicaments
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JPH11502816A (ja) * 1995-03-20 1999-03-09 イーライ・リリー・アンド・カンパニー ５−置換−３−（１，２，３，６−テトラヒドロピリジン−４−イル）−および３−（ピペリジン−４−イル）−１ｈ−インドール類：新規５−ｈｔ▲下１ｆ▼アゴニスト
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
JPH10512896A (ja) * 1995-11-14 1998-12-08 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー アリールおよびヘテロアリールプリン化合物
IL125824A0 (en) * 1996-02-23 1999-04-11 Dow Chemical Co Dispersions of delaminated particles in polymer foams
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
JP2001512727A (ja) 1997-08-09 2001-08-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
SE9903997D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
FR2814166B1 (fr) * 2000-09-21 2005-07-01 Innothera Lab Sa Derives 5-phenoxyindole et leurs applications therapeutiques
JP4253188B2 (ja) 2000-12-21 2009-04-08 グラクソ グループ リミテッド 血管新生制御剤としてのピリミジンアミン
CN1275967C (zh) * 2001-01-30 2006-09-20 伊莱利利公司 用作5－ht6受体拮抗剂的苯磺酸吲哚－5－基酯
MXPA03011244A (es) * 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
AU2004303461B2 (en) 2003-12-23 2011-04-28 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
JP2007535553A (ja) 2004-04-29 2007-12-06 アボット・ラボラトリーズ アミノ−テトラゾール類縁体および使用方法
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
BRPI0607517A2 (pt) 2005-04-13 2009-09-08 Neuraxon Inc compostos de indol substituìdo, composição farmacêutica compreendendo o mesmo, método para tratar e uso do mesmo
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
WO2007020652A1 (en) * 2005-08-12 2007-02-22 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands.
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
KR101415426B1 (ko) * 2005-09-27 2014-07-04 아이알엠 엘엘씨 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
CA2628260A1 (en) * 2005-11-09 2007-05-18 Abbott Laboratories 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof
TW200808780A (en) 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
KR20100103799A (ko) 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
EP2430019B1 (en) 2009-05-14 2013-09-18 Janssen Pharmaceutica, N.V. Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN102491935B (zh) * 2011-11-28 2013-10-16 山东大学 硝基苯甲醛吲哚席夫碱及其制备方法和应用
CN102584670B (zh) * 2012-01-15 2014-04-02 齐鲁工业大学 一种吲哚-3-甲醛缩苯二胺双席夫碱及其制备方法
CN102584671B (zh) * 2012-01-15 2013-08-07 山东轻工业学院 一种吲哚-3-甲醛缩联苯二胺双席夫碱及其制备方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
ES2788856T3 (es) 2017-03-20 2020-10-23 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313397A1 (en) * 1987-10-23 1989-04-26 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
EP0354777A2 (en) * 1988-08-10 1990-02-14 Glaxo Group Limited 3-(4-Piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
EP0405425A2 (en) * 1989-06-28 1991-01-02 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarylamino- and heteroaryloxypyridinamines and related compounds, a process for their preparation and their use as medicaments

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
PT97888B (pt) * 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
DE9112614U1 (de) * 1991-10-10 1992-01-16 Fleddermann, Jörg, 8000 München Kindersitz für Fahrzeuge mit Airbag
CA2124206C (en) * 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313397A1 (en) * 1987-10-23 1989-04-26 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
EP0354777A2 (en) * 1988-08-10 1990-02-14 Glaxo Group Limited 3-(4-Piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
EP0405425A2 (en) * 1989-06-28 1991-01-02 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarylamino- and heteroaryloxypyridinamines and related compounds, a process for their preparation and their use as medicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
96515G *
CHEMICAL ABSTRACT V01,107(EP2251726) 1987.10.1 CA107 *
CHEMICAL ABSTRACT V01,107(EP2251726) 1987.10.1 CA107;96515G *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123955B (zh) * 2004-12-23 2012-05-30 艾尼纳制药公司 5HT2c受体调节剂组合物及其制药用途

Also Published As

Publication number Publication date
PT101087A (pt) 1994-06-30
AU671959B2 (en) 1996-09-19
NO941918L (no) 1994-05-24
CZ281874B6 (cs) 1997-03-12
FI942395A7 (fi) 1994-05-24
YU100892A (sh) 1995-10-03
HU9401398D0 (en) 1994-08-29
YU48456B (sh) 1998-08-14
ZA929082B (en) 1994-05-24
ATE190608T1 (de) 2000-04-15
NZ272130A (en) 1997-06-24
DE69230803T2 (de) 2000-12-07
WO1993011106A1 (en) 1993-06-10
NO301225B1 (no) 1997-09-29
CA2124206C (en) 2001-02-27
DE69230803D1 (de) 2000-04-20
UA41297C2 (uk) 2001-09-17
CZ128094A3 (en) 1995-02-15
TW229205B (cg-RX-API-DMAC7.html) 1994-09-01
RU2126399C1 (ru) 1999-02-20
ES2143992T3 (es) 2000-06-01
US5639752A (en) 1997-06-17
EP0619805A1 (en) 1994-10-19
JP2840448B2 (ja) 1998-12-24
FI942395A0 (fi) 1994-05-24
CA2124206A1 (en) 1993-06-10
GR3033370T3 (en) 2000-09-29
NZ245243A (en) 1995-12-21
PL173875B1 (pl) 1998-05-29
DK0619805T3 (da) 2000-06-05
JPH06510793A (ja) 1994-12-01
JPH08239363A (ja) 1996-09-17
IL103798A0 (en) 1993-04-04
MX9206762A (es) 1993-05-01
RU94028107A (ru) 1996-04-10
EG21209A (en) 2001-01-31
MY109954A (en) 1997-10-31
EP0619805B1 (en) 2000-03-15
IL103798A (en) 2000-08-13
KR0184911B1 (ko) 1999-05-01
AU2896192A (en) 1993-06-28
NO941918D0 (no) 1994-05-24
BR9206810A (pt) 1995-10-31
HUT69705A (en) 1995-09-28
CN1072679A (zh) 1993-06-02
PT101087B (pt) 1999-10-29

Similar Documents

Publication Publication Date Title
CN1045294C (zh) 吲哚衍生物的制备方法
CN1051313C (zh) 5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体
CN1229351C (zh) 杂环化合物和治疗心力衰竭及其它疾病的方法
CN1072220C (zh) 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
CN1149051A (zh) 用作α1-肾上腺素能受体拮抗剂的嘧啶二酮、嘧啶三酮、三嗪二酮、四氢喹唑啉二酮衍生物
CN1665502A (zh) Mchir拮抗剂
CN1639147A (zh) 4,5－二氢－吡唑并[3,4－c]吡啶－2－酮类化合物的合成
CN1085556A (zh) 抗偏头痛的吲哚-3-基烷基哌嗪的4-嘧啶基和吡啶基衍生物
CN1062529A (zh) 吲哚衍生物
CN1434811A (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
HK1041483A1 (en) Bicyclic nitrogen heterocycles
CN1436188A (zh) 用作神经激肽受体拮抗剂的1,3,8－三氮杂－螺[4,5]癸－4－酮衍生物
CN1409703A (zh) 4－氨基哌啶衍生物和它们作为药物的用途
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1812980A (zh) 哌啶基－和哌嗪基－烷基氨基甲酸酯衍生物,其制备及治疗用途
CN1230432C (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1668585A (zh) 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
CN1604897A (zh) 作为腺苷受体配体的7－氨基苯并噻唑衍生物
CN1585763A (zh) 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途
CN1092765A (zh) 新的色胺类似物及其制备方法与用途
CN1589261A (zh) 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途
CN1639121A (zh) 具有鸦片样受体亲合性的3－氮杂二环并(3.1.0)己烷衍生物
CN1438996A (zh) 二环环己胺类化合物及其作为nmda受体拮抗剂的应用
CN1314345A (zh) 新的哌啶－4－磺酰胺化合物、其制备方法和含有它们的药物组合物
CN1037895A (zh) 杂脂族羧酰胺类化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee